Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic hematopoietic stem cell transplantation vs chemotherapy for T-cell lymphoma (multicenter China, phase 2)
ChiCTR2300071352Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic hematopoietic stem cell transplantation in T-cell lymphoma, peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL) and 4 more (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
allogeneic hematopoietic stem cell transplantation
03
Conditions
T-cell lymphomaperipheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)enteropathy-associated T-cell lymphoma (EATL)
Beyond the preview
Go deeper on ChiCTR2300071352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071352.